Hims vs Novo Nordisk, Running vs at-home fitness, Women's performance research scores $50M

February 6, 2026: Your daily rundown of health and wellness news, in under 5 minutes.

Today's top stories:

• Hims launches compounded GLP-1 pill starting at $49/month as needle-free alternative, but Novo Nordisk threatens legal action over what it calls illegal compounding

• Women's Health, Sports, and Performance Medical Institute launches with $50M+ to fund injury prevention research for female athletes

• Peloton reports Q2 revenue of $656.5M missing expectations with paid subscribers down 7% year-over-year, while Brooks reports revenue up 16% marking ninth straight year of growth

More from Fitt:

Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital.

Subscribe to our newsletter → insider.fitt.co/subscribe

Work with our recruiting firm → https://talent.fitt.co/

Follow us on Instagram → https://www.instagram.com/fittinsider/

Follow us on LinkedIn → linkedin.com/company/fittinsider

Reach out → [email protected]